(NewsDirect)
Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive thecompany’s Phase 1 MAST (metastatic advanced solid tumours) studyevaluating the safety of novel cancer-killing virus CF33-hNIS(VAXINIA) has seen the first patients dosed in the intravenous andintratumoral (IT) cohorts in combination with Pembrolizumab. Overallthe study aims to recruit up to 100 patients across around 10 trialsites in the United States and Australia.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.